%0 Journal Article
%T SGLT2抑制剂在肾脏保护方面的研究进展<br>Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney
%A 姜玉娇
%A 梅峰
%J Advances in Clinical Medicine
%P 3926-3930
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.125569
%X 钠–葡萄糖协同转运蛋白2 (sodium-glucose cotransporter-2, SGLT2)抑制剂是一种新型降糖药物，在降糖的同时可改善2型糖尿病患者心血管及肾脏结局。近期研究发现，其在治疗非糖尿病导致的慢性肾脏病(chronic kidney disease, CKD)同样具有肾脏保护作用，这为CKD的治疗提供了新方向和新思路。现对于SGLT2抑制剂治疗CKD的作用机制以及安全性仍在探索中，本文就SGLT2抑制剂在肾脏获益方面的研究进展及其可能的机制进行简要综述，旨在为CKD患者的治疗提供临床参考。<br />
Sodium-glucose cotransporter-2 (sodium-glucose cotransporter-2, SGLT2) inhibitor is a novel hypo-glycemic drug that can improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. Recent studies have found that it also has renal protective effect in the treatment of chronic kidney disease (CKD) not caused by diabetes, which provides a new direction and new ideas for the treatment of CKD. Currently, the mechanism and safety of SGLT2 inhibitors in the treatment of CKD are still being explored. In this review, the research progress of SGLT2 inhibitors in kidney benefit and their possible mechanisms are briefly reviewed, aiming to provide clinical reference for the treatment of patients with CKD.
%K SGLT2抑制剂，肾脏保护，慢性肾脏病<br>SGLT2 Inhibitor
%K Renal Protective Effect
%K Chronic Kidney Disease
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=51277